Coya Therapeutics Shares Outstanding History (COYA)
Coya Therapeutics reported 20.9M shares outstanding at the end of fiscal 2025.
View full Coya Therapeutics company overviewCoya Therapeutics annual shares outstanding history
| Fiscal year | Period ended | Shares outstanding | Change | Growth |
|---|---|---|---|---|
| 2025 | 2025-12-31 | 20.9M | 4.2M | +25.30% |
| 2024 | 2024-12-31 | 16.7M | 2.3M | +15.98% |
| 2023 | 2023-12-31 | 14.4M | 11.8M | +456.15% |
| 2022 | 2022-12-31 | 2.6M | 146 | +0.01% |
| 2021 | 2021-12-31 | 2.6M | — | — |
Coya Therapeutics quarterly shares outstanding
| Fiscal quarter | Period ended | Shares outstanding | Change | YoY change |
|---|---|---|---|---|
| Q2 2026 | 2026-06-30 | 23.5M | 6.7M | +40.26% |
| Q1 2026 | 2026-03-31 | 23.5M | 6.7M | +40.25% |
| Q4 2025 | 2025-12-31 | 20.9M | 4.2M | +25.30% |
| Q3 2025 | 2025-09-30 | 16.7M | 1.5M | +9.99% |
| Q2 2025 | 2025-06-30 | 16.7M | 1.5M | +9.88% |
| Q1 2025 | 2025-03-31 | 16.7M | 2.1M | +14.45% |
| Q4 2024 | 2024-12-31 | 16.7M | 2.3M | +15.98% |
| Q3 2024 | 2024-09-30 | 15.2M | 5.3M | +53.01% |
| Q2 2024 | 2024-06-30 | 15.2M | 5.3M | +53.01% |
| Q1 2024 | 2024-03-31 | 14.6M | 4.7M | +46.90% |
| Q4 2023 | 2023-12-31 | 14.4M | 11.8M | +456.16% |
| Q3 2023 | 2023-09-30 | 9.9M | 7.4M | +284.08% |
| Q2 2023 | 2023-06-30 | 9.9M | — | — |
| Q1 2023 | 2023-03-31 | 9.9M | — | — |
| Q4 2022 | 2022-12-31 | 2.6M | — | — |
| Q4 2021 | 2021-12-31 | 2.6M | — | — |
Coya Therapeutics shares outstanding trends
Across the available reported history, Coya Therapeutics's shares outstanding moved from 16.7M to 20.9M, a change of 4.2M. The latest reported quarter, Q2 2026, shows 23.5M.
What shares outstanding means
Shares outstanding is the number of common shares held by investors at a reporting-period end. The count can change because of stock issuance, repurchases, conversions, acquisitions, or stock splits.
SEC-reported period-end shares
TickerStat displays period-end common shares from SEC filings and adjusts older values to the current share basis when SEC-reported stock-split conversion ratios are available. Values remain as reported when no split ratio is available. Fiscal periods can differ from calendar years, so exact period-end dates are included.
Review Coya Therapeutics filings at SEC.gov ↗